Tracer library / [68Ga]177-AAZTA5-PSMA-617

[68Ga]177-AAZTA5-PSMA-617

Radionuclide
Ga-68 t½ 67.71 min
Modality
PET
Production route
—
Stage
Preclinical
Syntheses indexed
1
Prostate cancerPreclinical only, no clinical indication yet

What it is

Compound class
AAZTA5-PSMA-617 (urea-based PSMA-targeting small molecule with AAZTA5 chelator)
Target / mechanism
PSMA (prostate-specific membrane antigen) binding PMID 33242189
Clinical application
Prostate cancer theranostics PMID 33242189
Theranostic pair
[177Lu]Lu-177-AAZTA5-PSMA-617

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis—none>99%99.9%AAZTA5-PSMA-61733242189
2020 EJNMMI Radiopharm Chem
Labeling with 68Ga and 177Lu were performed in 1 ml of 0.2 M ammonium acetate buffer pH 4.5 at room temperature (25 °C). - radiolabeled in quantitative radiochemical yields (> 99%, as determined both by radio-HPLC and radio-TLC)

Need this precursor?We can point you to suppliers for [68Ga]177-AAZTA5-PSMA-617, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33242189. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33242189: 'AAZTA5-PSMA-617 (AAZTA5-Chx-2-NaI-Lys-Urea-Glu) was successfully radiolabeled'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 33242189. Stage set/updated at stage 39 from PMID 33242189: 'In vitro studies on PSMA-positive LNCaP cells were performed in direct comparison to radiolabeled DOTA-PSMA-617'.
Ask a question